Discussion
tumor, thyroid carcinomas
THYROID CARCINOMA, TUMOR, NEOPLASMS, DEDIFFERENTIATION, SECONDARY, THYROID NEOPLASMS, THYROID CANCER
When performing and interpreting [To the best of knowledge, our study is the first to assess immunohistochemical staining for metabolic markers in comparison to [The previous, heterogeneous studies of these markers in thyroid carcinomas showed mixed results, possibly hindered by their oftentimes limited sample size and statistical power [The current study does not resolve the origin of the enhanced glucose metabolism and increased [Hürthle cell neoplasms are considered a separate entity among the follicular cell-derived thyroid neoplasms. They are distinct in their clinical and biological behavior and carry different genetic alterations, primarily characterized by copy number alterations [In previous studies in thyroid cancer, correlations were established between various metabolic markers and signs of adverse prognosis. For example, GLUT1 overexpression was associated with tumor dedifferentiation, lymph node metastasis, and shorter overall survival [The main limitations of the current study were its case–control design, which is susceptible to selection bias, and its limited sample size. The latter limited the statistical power and may have caused underreporting of any effects. As the study was designed as a secondary and explorative analysis of data acquired during a randomized controlled trial, the current study was not powered in advance to distinguish differences in immunohistochemical staining. In addition, during the interpretation of the data, it was assumed that the degree of immunohistochemical expression of metabolic markers positively correlated with the functional activity of these proteins. This assumption may not necessarily be correct and may be considered a general limitation of immunohistochemical studies. For example, immunohistochemical expression of NIS is not an accurate predictor of radioiodine uptake [In conclusion, the positive correlations between [